Palvella Therapeutics (PVLA) Asset Writedowns and Impairment (2023)
Palvella Therapeutics' (PVLA) quarterly Asset Writedowns and Impairment came in at -$981000.0 in Q4 2023, down 106.59% on a QoQ basis from $14.9 million in Q3 2023.
Palvella Therapeutics (PVLA) Asset Writedowns and Impairment (2023) Analysis & Trends
Palvella Therapeutics (PVLA) has 1 years of Asset Writedowns and Impairment data on file, last reported at -$981000.0 in Q4 2023.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$981000.0 in Q4 2023; TTM through Sep 2024 was $13.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $13.9 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2023 stood at -$981000.0, down from $14.9 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for PVLA reached as high as $14.9 million in Q3 2023 and fell as low as -$981000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.86 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -981,000.00 |
| Dec 31, 2023 | -981,000.00 |
| Sep 30, 2023 | 14.89 Mn |
| Sep 30, 2023 | 14.89 Mn |